The Patent Finder
PL

Plexxikon Inc.

First filing 2003
OverviewNotableFeesChangesFamiliesPatent listSources & methods

53 patents currently held

38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2027. from the record

Of the 38 now held by other companies, 20 name Daiichi Sankyo Inc. as their current owner, and 18 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
22
Ending by 2030
Aug 2027
Next term end
40
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Compounds and Methods for Kinase Modulation, and Indications Therefor US 7,863,288
The most cited patent in this portfolio, cited by 166 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2029.
Ends Jun 2029 · High confidence
Also notable
Compounds and Methods for Kinase Modulation, and Indications Therefor US 11,337,976
Cited by 40 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2032.
Ends Feb 2032 · High confidence
Also notable
Compounds and Methods for Kinase Modulation, and Indications Therefor US 9,469,640
Cited by 51 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2028.
Ends Jul 2028 · High confidence

Formerly held, still cited

Notable
Cited by 71 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.
now held by Opna Bio S.A.
Ends Mar 2034 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Compounds and Methods for Kinase Modulation, and Indications Therefor (US 10,301,280) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 1 fee due Dec 11, 2026
    The maintenance fee for Solid Forms of a Compound for Modulating Kinases (US 10,316,032) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
  • 2 fees due Feb 4 to 28, 2027 · next Feb 4
  • 1 fee due Mar 24, 2027
    The maintenance fee for Compounds for Kinase Modulation, and Indications Therefor (US 10,421,761) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
  • 3 fees due Apr 1 to 6, 2027 · next Apr 1
  • 1 fee due Jun 17, 2027
    The maintenance fee for Compounds and Methods for Ido and Tdo Modulation, and Indications Therefor (US 10,508,085) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
  • 1 fee due Aug 16, 2027
    The maintenance fee for Compounds and Methods for Kinase Modulation, and Indications Therefor (US 9,260,437) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,415,469Compounds and Methods for Kinase Modulation, and Indications Therefor
In force
 · High confidence
In forceHigh confidence
US 7,585,859PDE4B Inhibitors and Uses Therefor
In force
 · High confidence
In forceHigh confidence
US 7,605,168PDE4B Inhibitors
In force
 · High confidence
In forceHigh confidence
US 9,469,640Compounds and Methods for Kinase Modulation, and Indications Therefor
In force
 · High confidence
In forceHigh confidence
US 9,844,539Compounds and Methods for Kinase Modulation, and Indications Therefor
In force
 · High confidence
In forceHigh confidence
US 10,426,760Compounds and Methods for Kinase Modulation, and Indications Therefor
In force
 · High confidence
In forceHigh confidence
US 7,846,941Compounds Modulating C-Kit and C-Fms Activity and Uses Therefor
In force
 · High confidence
In forceHigh confidence
US 7,863,289Compounds and Methods for Kinase Modulation, and Indications Therefor
In force
 · Medium confidence
In forceMedium confidence
US 9,260,437Compounds and Methods for Kinase Modulation, and Indications Therefor
In force
 · High confidence
In forceHigh confidence
US 8,110,576Substituted PYRROLO[2,3B]PYRAZINES and Methods for Treatment of Raf Protein Kinase-Mediated Indications
In force
 · Medium confidence
In forceMedium confidence
10 of 53 patents shown.
Pro members see all 53.
Pro members: see all 53 patents
Also on record, not counted in the 53: 38 patents in force now held by others · 15 patents ended · 3 applications pending · 58 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited